“Markets aren’t pricing in mutation risk”
[et_pb_section fb_built=”1″ _builder_version=”4.6.0″ _module_preset=”default”][et_pb_row _builder_version=”4.6.0″ _module_preset=”default”][et_pb_column _builder_version=”4.6.0″ _module_preset=”default” type=”4_4″][et_pb_text _builder_version=”4.6.0″ _module_preset=”default” hover_enabled=”0″ sticky_enabled=”0″] Veteran stock picker Hamish Douglas (of Magellan) sees no shortage of the risks including that covid-19 mutations could render current vaccines ineffective. The spread of the Delta variant from Australia’s most populous city to other states hasn’t worried the equity market so … “Markets aren’t pricing in mutation risk”
